Long-term outcomes of autologous tranplantation in multiple myeloma: Significant survival benefit of novel drugs in post-transplantation relapse.
| Authors | |
|---|---|
| Year of publication | 2009 |
| Type | Article in Periodical |
| Magazine / Source | Clinical Lymphoma & Myeloma |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | bortezomib; complete response; thalidomide |
| Description | Autologous stem cell transplantation (autoSCT) has an important role in the treatment of patients with symptomatic multiple myeloma (MM). Treatment options for myeloma have expanded in the past decade, and it seems that patients who are treated with novel drugs such as thalidomide and bortezomib for relapse after autoSCT have longer overall survival (OS). |
| Related projects: |